Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences Sep 18, 2025 08:30AM
Wave Life Sciences reports positive data from AATD drug trial Sep 3, 2025 07:30AM
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency Sep 3, 2025 07:30AM
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update Jul 30, 2025 07:30AM
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 Jul 23, 2025 08:30AM
View Older Stories

Jun 20, 2025 04:02PM Wave Life Sciences (WVE) Announces Oral Presentation of Preclinical Data Supporting WVE-007
Jun 20, 2025 04:01PM Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Se
Jun 20, 2025 04:01PM Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientif
May 29, 2025 08:30AM Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
May 28, 2025 08:01AM WAVE Life Sciences (WVE) Appoints Christopher Wright as Chief Medical Officer
May 28, 2025 08:00AM Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
May 8, 2025 07:30AM Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 1, 2025 08:30AM Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
Mar 26, 2025 07:31AM WAVE Life Sciences (WVE) Announces Positive Data from FORWARD-53 Clinical Trial in DMD
Mar 26, 2025 07:30AM Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
Mar 4, 2025 07:30AM Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Feb 25, 2025 08:30AM Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
Feb 6, 2025 08:31AM WAVE Life Sciences (WVE) announces phase 1 of clinic trial of WVE-007
Feb 6, 2025 08:30AM Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
Jan 13, 2025 09:00AM Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
Dec 23, 2024 08:30AM Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
Dec 16, 2024 08:30AM Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
Nov 26, 2024 08:30AM Wave Life Sciences to Present at Upcoming Investor Conferences
Nov 15, 2024 08:30AM Wave Life Sciences to Present at Jefferies London Healthcare Conference
Nov 12, 2024 07:30AM Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 4, 2024 04:05PM Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
Oct 30, 2024 04:45PM Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
Oct 16, 2024 08:52AM WAVE Life Sciences (WVE) Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Oct 16, 2024 08:30AM Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Oct 16, 2024 08:25AM Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
Sep 30, 2024 08:30AM Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
Sep 24, 2024 07:34AM WAVE Life Sciences (WVE) Announces Positive Interim Data from FORWARD-53 Trial of WVE-N531
Sep 24, 2024 07:30AM Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Aug 12, 2024 08:32AM WAVE Life Sciences (WVE) Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
Aug 12, 2024 08:30AM Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
Aug 8, 2024 07:30AM Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Aug 1, 2024 08:30AM Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024
Jun 25, 2024 07:31AM WAVE Life Sciences (WVE) Announces Positive Results from Phase 1b/2a SELECT-HD Trial
Jun 25, 2024 07:30AM Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Jun 12, 2024 08:30AM Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
May 30, 2024 08:30AM Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
May 9, 2024 07:30AM Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 9, 2024 07:02AM WAVE Life Sciences (WVE) Appoints Erik Ingelsson as Chief Scientific Officer
May 9, 2024 07:00AM Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
May 7, 2024 08:30AM Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
May 2, 2024 08:30AM Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
Apr 30, 2024 08:33AM WAVE Life Sciences (WVE) Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency
Apr 30, 2024 08:30AM Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
Apr 23, 2024 08:30AM Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
Mar 27, 2024 08:30AM Wave Life Sciences to Present at Upcoming Investor Conferences
Mar 6, 2024 07:30AM Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb 28, 2024 08:30AM Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
Feb 27, 2024 08:30AM Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
Jan 8, 2024 08:00AM Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
Jan 3, 2024 08:30AM Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
View Older Stories